This comparative analysis examines FHLC and IYH, two healthcare-focused exchange-traded funds, through the lens of portfolio composition and structural risk-return characteristics. The distinction between these vehicles hinges on asset size, stock selection methodology, and resulting tracking efficiency—factors that directly influence expense ratios, liquidity, and replication quality in the healthcare sector.
The divergence in holdings and weighting schemes between the two ETFs creates meaningful differences in sector concentration and individual pharma/biotech exposure. FHLC and IYH may track different healthcare indices or employ distinct screening criteria, leading to varied exposure to mega-cap names like JNJ and ABBV versus mid-cap and specialty healthcare players. Portfolio turnover and tax efficiency also vary materially across these structures.
The utility of this comparison centers on investor objective alignment: passive replication fidelity, cost minimization, or sector tilt preferences. Broader healthcare fundamentals—drug pricing pressures, patent cliff dynamics, and regulatory risk—affect both vehicles equivalently, but their internal construction determines relative downside protection and upside capture in volatile biotech environments.
Sector implication: Healthcare ETF selection reflects macro conviction on sector resilience and inflation-hedging demand. The proliferation of specialized healthcare funds signals investor demand for targeted exposure beyond broad-market allocation, with fund structure increasingly determining alpha relative to peers rather than fundamental thesis divergence.